88 related articles for article (PubMed ID: 18465026)
1. Chaperone proteins identified from synthetic proteasome inhibitor-induced inclusions in PC12 cells by proteomic analysis.
Li X; Zhang Y; Hu Y; Chang M; Liu T; Wang D; Zhang Y; Zhang L; Hu L
Acta Biochim Biophys Sin (Shanghai); 2008 May; 40(5):406-18. PubMed ID: 18465026
[TBL] [Abstract][Full Text] [Related]
2. Proteomic characterization of an isolated fraction of synthetic proteasome inhibitor (PSI)-induced inclusions in PC12 cells might offer clues to aggresomes as a cellular defensive response against proteasome inhibition by PSI.
Li X; Zhang Y; Xie P; Piao J; Hu Y; Chang M; Liu T; Hu L
BMC Neurosci; 2010 Aug; 11():95. PubMed ID: 20704702
[TBL] [Abstract][Full Text] [Related]
3. Proteomic changes of PC12 cells treated with proteasomal inhibitor PSI.
Zhang L; Chang M; Li H; Hou S; Zhang Y; Hu Y; Han W; Hu L
Brain Res; 2007 Jun; 1153():196-203. PubMed ID: 17490626
[TBL] [Abstract][Full Text] [Related]
4. Differential protein profile of PC12 cells exposed to proteasomal inhibitor lactacystin.
Hu X; Zhang H; Zhang Y; Zhang Y; Bai L; Chen Q; Wu J; Zhang L
Neurosci Lett; 2014 Jul; 575():25-30. PubMed ID: 24858133
[TBL] [Abstract][Full Text] [Related]
5. Proteomic Study of a Parkinson's Disease Model of Undifferentiated SH-SY5Y Cells Induced by a Proteasome Inhibitor.
Jiang H; Yu Y; Liu S; Zhu M; Dong X; Wu J; Zhang Z; Zhang M; Zhang Y
Int J Med Sci; 2019; 16(1):84-92. PubMed ID: 30662332
[TBL] [Abstract][Full Text] [Related]
6. Releasing the Lockdown: An Emerging Role for the Ubiquitin-Proteasome System in the Breakdown of Transient Protein Inclusions.
Reiss Y; Gur E; Ravid T
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32784966
[TBL] [Abstract][Full Text] [Related]
7. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
[TBL] [Abstract][Full Text] [Related]
8. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation.
Waelter S; Boeddrich A; Lurz R; Scherzinger E; Lueder G; Lehrach H; Wanker EE
Mol Biol Cell; 2001 May; 12(5):1393-407. PubMed ID: 11359930
[TBL] [Abstract][Full Text] [Related]
9. In PC12 cells neurotoxicity induced by methamphetamine is related to proteasome inhibition.
Lazzeri G; Lenzi P; Gesi M; Ferrucci M; Fulceri F; Ruggieri S; Bruno V; Fornai F
Ann N Y Acad Sci; 2006 Aug; 1074():174-7. PubMed ID: 17105915
[TBL] [Abstract][Full Text] [Related]
10. Proteomic expression analysis of cardiomyocytes subjected to proteasome inhibition.
Doll D; Sarikas A; Krajcik R; Zolk O
Biochem Biophys Res Commun; 2007 Feb; 353(2):436-42. PubMed ID: 17174276
[TBL] [Abstract][Full Text] [Related]
11. The Mrj co-chaperone mediates keratin turnover and prevents the formation of toxic inclusion bodies in trophoblast cells of the placenta.
Watson ED; Geary-Joo C; Hughes M; Cross JC
Development; 2007 May; 134(9):1809-17. PubMed ID: 17409114
[TBL] [Abstract][Full Text] [Related]
12. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues.
Watanabe M; Dykes-Hoberg M; Culotta VC; Price DL; Wong PC; Rothstein JD
Neurobiol Dis; 2001 Dec; 8(6):933-41. PubMed ID: 11741389
[TBL] [Abstract][Full Text] [Related]
13. Intragastric proteasome inhibition induces alpha-synuclein-immunopositive aggregations in neurons in the dorsal motor nucleus of the vagus in rats.
Miwa H; Kubo T; Suzuki A; Kondo T
Neurosci Lett; 2006 Jun; 401(1-2):146-9. PubMed ID: 16600504
[TBL] [Abstract][Full Text] [Related]
14. Targeted disruption of neuronal 19S proteasome subunits induces the formation of ubiquitinated inclusions in the absence of cell death.
Droggiti A; Ho CC; Stefanis L; Dauer WT; Rideout HJ
J Neurochem; 2011 Nov; 119(3):630-43. PubMed ID: 21883213
[TBL] [Abstract][Full Text] [Related]
15. Autophagy inhibition promotes defective neosynthesized proteins storage in ALIS, and induces redirection toward proteasome processing and MHCI-restricted presentation.
Wenger T; Terawaki S; Camosseto V; Abdelrassoul R; Mies A; Catalan N; Claudio N; Clavarino G; de Gassart A; Rigotti Fde A; Gatti E; Pierre P
Autophagy; 2012 Mar; 8(3):350-63. PubMed ID: 22377621
[TBL] [Abstract][Full Text] [Related]
16. Biochemical features of ceruloplasmin gene mutations linked to aceruloplasminemia.
Kono S; Suzuki H; Oda T; Miyajima H; Takahashi Y; Shirakawa K; Ishikawa K; Kitagawa M
Neuromolecular Med; 2006; 8(3):361-74. PubMed ID: 16775387
[TBL] [Abstract][Full Text] [Related]
17. Mallory-Denk-bodies: lessons from keratin-containing hepatic inclusion bodies.
Strnad P; Zatloukal K; Stumptner C; Kulaksiz H; Denk H
Biochim Biophys Acta; 2008 Dec; 1782(12):764-74. PubMed ID: 18805482
[TBL] [Abstract][Full Text] [Related]
18. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
[TBL] [Abstract][Full Text] [Related]
19. Different induction of GRP78 and CHOP as a predictor of sensitivity to proteasome inhibitors in thyroid cancer cells.
Wang HQ; Du ZX; Zhang HY; Gao DX
Endocrinology; 2007 Jul; 148(7):3258-70. PubMed ID: 17431003
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical localization of aggresomal proteins in glial cytoplasmic inclusions in multiple system atrophy.
Chiba Y; Takei S; Kawamura N; Kawaguchi Y; Sasaki K; Hasegawa-Ishii S; Furukawa A; Hosokawa M; Shimada A
Neuropathol Appl Neurobiol; 2012 Oct; 38(6):559-71. PubMed ID: 22013984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
